Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats

Brittany D. Partain1, Evelyn Bracho-Sanchez1, Shaheen A. Farhadi1, Elena G. Yarmola1, Benjamin G. Keselowsky1, Gregory A. Hudalla1 and Kyle D. Allen1,2*

Abstract

Objective Osteoarthritis (OA) is driven by low-grade inflammation, and controlling local inflammation may offer symptomatic relief. Here, we developed an indoleamine 2,3-dioxygenase and galectin-3 fusion protein (IDO-Gal3), where IDO increases the production of local anti-inflammatory metabolites and Gal3 binds carbohydrates to extend IDO's joint residence time. In this study, we evaluated IDO-Gal3's ability to alter OA-associated inflammation and pain-related behaviors in a rat model of established knee OA.

Methods Joint residence was first evaluated with an analog Gal3 fusion protein (NanoLuc™ and Gal3, NL-Gal3) that produces luminescence from furimazine. OA was induced in male Lewis rats via a medial collateral ligament and medial meniscus transection (MCLT + MMT). At 8 weeks, NL or NL-Gal3 were injected intra-articularly (n = 8 per group), and bioluminescence was tracked for 4 weeks. Next, IDO-Gal3's ability to modulate OA pain and inflammation was assessed. Again, OA was induced via MCLT + MMT in male Lewis rats, with IDO-Gal3 or saline injected into OA-affected knees at 8 weeks post-surgery (n = 7 per group). Gait and tactile sensitivity were then assessed weekly. At 12 weeks, intra-articular levels of IL6, CCL2, and CTXII were assessed.

Results The Gal3 fusion increased joint residence in OA and contralateral knees (p < 0.0001). In OA-affected animals, both saline and IDO-Gal3 improved tactile sensitivity (p = 0.008), but IDO-Gal3 also increased walking velocities (p ≤ 0.033) and improved vertical ground reaction forces (p ≤ 0.04). Finally, IDO-Gal3 decreased intra-articular IL6 levels within the OA-affected joint (p = 0.0025).

Conclusion Intra-articular IDO-Gal3 delivery provided long-term modulation of joint inflammation and pain-related behaviors in rats with established OA.

Keywords Knee osteoarthritis, Indoleamine 2,3-dioxygenase, Galectin-3, Metabolic reprogramming, Intra-articular drug delivery, Inflammation, Pain and disability

Introduction Osteoarthritis (OA) is the most common form of arthritis, causing pain and/or disability in 32.5 million US adults. As OA pathology and symptoms are often associated with chronic local, low-grade inflammation [1], controlling joint inflammation can be important for both disease modification and symptomatic control [2]. Current OA treatments include oral non-steroidal...
anti-inflammatory drugs (NSAIDs) and intra-articular injections of corticosteroids or hyaluronic acid [3]. Although intra-articular injections increase the local concentration of an anti-inflammatory drug and decrease off target effects, the efficacy of this approach is often hindered by rapid joint clearance. Short joint residence times typically necessitate repeated injections, which can lead to increased risk of infection and chondrocyte death [4–6]. As such, multiple developmental intra-articular delivery strategies have aimed to extend the joint residence times of anti-inflammatory agents [7]. For example, therapeutics are commonly encapsulated in carriers that extend joint residence; however, harsh encapsulation conditions can reduce a drug’s bioactivity [8, 9]. Alternatively, conjugating protein-based drugs to synthetic particles can extend joint residence, improve bioactivity, and limit degradation [10]; however, determining an effective dose to circumvent joint clearance and maintain efficacy has proven difficult [11].

Relating to the current challenges of intra-articular drug delivery, enzyme-based therapeutics may offer an advantage [12]. With the catalytic capabilities of enzymes, target molecules can be continually and locally produced, as long as the enzyme’s substrate is available. This decreases the necessary dose of the enzyme. Moreover, conjugating enzymes to anchoring molecules can further enhance bioactivity and extend joint residence. Thereby, enzyme-based therapeutics could offer the advantage of maintaining local drug concentrations (via the catalytic capability of the enzyme) and the ability to extend joint residence via fusion of the enzyme to matrix anchoring peptides.

To provide long-lasting local control of inflammation, we developed an indoleamine 2,3-dioxygenase galexctin-3 fusion protein (IDO-Gal3). IDO is an immunomodulatory enzyme that converts tryptophan into kynurenines [13–16]. By locally degrading tryptophan, IDO induces effector T cell apoptosis, promotes regulatory T cell proliferation, modulates macrophage differentiation toward an anti-inflammatory phenotype, and maintains an immature phenotype on dendritic cells that results in suppression of antigen-specific T cell proliferation [15, 17–19]. Gal3 binds to β-galactoside glycoconjugates and glycosaminoglycans, and these sites are prevalent in multiple joint tissues. Via this binding, Gal3 can extend an enzyme’s local residence time [20, 21]. We have previously explored the immunomodulatory ability of IDO and the ability of IDO-Gal3 to modulate local inflammation [22]. In this study, the ability of IDO-Gal3 is specifically evaluated for its ability to modulate OA-related inflammation and symptoms subsequent to a surgically-simulated meniscal injury in the rat. While OA tends to have a lower inflammatory profile than other arthritides, chronic low-grade inflammation remains a key driver of OA progression [1]. Moreover, the chronic nature of this inflammation often requires sustained delivery over long time periods to affect inflammation and symptoms. As such, this study explores IDO-Gal3’s ability to alter OA-associated inflammation and pain-related behaviors in a rat model of established knee OA, delivering IDO-Gal3 only after the onset of OA-related symptoms and at a timepoint associated with full-thickness cartilage lesions.

Methods
Experimental designs
Animal procedures were approved by the University of Florida’s Institutional Animal Care and Use Committee (UF IACUC #202011223). For all experiments, male Lewis rats (250 g, approximately 12 weeks old based on Lewis rat growth charts) were acquired from Charles River Laboratories (Wilmington, MA, USA) and acclimated to the University of Florida for 1 week prior to any use. Animals were co-housed with standard bedding and food/water provided ad libitum. Following survival surgeries or intra-articular injections, animals were evaluated daily for evidence of infection, non-weight bearing behavior, or other signs of distress (body condition score, perforin, unusual stool). Evaluations were performed independently by both study staff and UF animal care service technician. If concerns were raised by either party, staff consulted with veterinarians to develop a treatment plan or select a humane endpoint. All incidences of humane endpoints or additional treatment are described in the experiment designs below.

In our first experiment, joint retention of a Gal3 fusion protein was assessed (Supplemental Fig. 1). Here, 16 male Lewis rats underwent a medial collateral ligament and medial meniscus transaction surgery (MCLT+MMT). At 8 weeks post-surgery, rats were assigned to random groups and background luminescence was measured for each rat (1 s exposure, field of view D, PerkinElmer IVIS, Waltham, MA, USA). Both knees were then injected with either 50 µL NanoLuc™ Luciferase (NL, n=8, 3.27 µM) or a NanoLuc™ Luciferase galexctin-3 fusion protein (NL-Gal3, n=8, 3.27 µM). For luminescence imaging, knees were injected with 50 µL furimazine (1:50 dilution in PBS, Nano-Glo™, PRN1120, Promega, Madison, WI, USA), then assessed with the above IVIS settings. Luminescence imaging was repeated 1, 2, 4, 8, 12, 16, 20, 24, and 28 days after NL or NL-Gal3 injection. On day 28, rats were euthanized via exsanguination under deep anesthesia, and the patella, tibia, femur, and meniscus were dissected, preserving the synovium and fat pad connected to each bone. Tissue samples were placed in a 24-well plate and incubated with diluted furimazine for 1 min at 25°C. After incubation, tissues were removed,
and luminescence was measured using the autoexposure setting in field of view C. For context, the estimated physical properties of NL, NL-Gal3, IDO, and IDO-Gal3 are provided in Supplemental Table 1.

In our second experiment, we evaluated IDO’s ability to modulate OA-related inflammation and symptoms (Supplemental Fig. 2). Here, 16 additional male Lewis rats (250 g, 3 months) underwent baseline behavioral testing followed by MCLT + MMT surgery; one rat was euthanized due to surgical complications (irreparable wound dehiscence). Post-surgery, rodent gait was assessed at 3, 5, and 7 weeks and tactile sensitivity was assessed weekly (except for week 6 due to university closure related to a hurricane warning). At 8 weeks post-surgery, rats received 30 µL injections of either saline (n = 7) or IDO-Gal3 (n = 8, 0.5 nM) in the MCLT + MMT knee. Tactile sensitivity testing was conducted the day after injection, then weekly out to 11 weeks post-surgery. Gait testing was performed 2 days after injection, then weekly out to 11 weeks post-surgery. Rats were then euthanized via exsanguination under deep anesthesia. Immediately post-mortem, IL6, CCL2, and CTXII were assessed in both knees using magnetic capture. Here, saline samples from a contralateral and operated limb were lost due to insufficient collection of magnetic beads. Following magnetic capture, the knees were processed for histology. In histology, one IDO-Gal3-treated rat showed an intact medial meniscus (failure to fully transect the meniscus); this animal was removed from the analysis. Thus, the final datasets are n = 6–7 for saline treatment and n = 7 for IDO-Gal3 treatment.

Following surgery, one rat was euthanized due to surgical complications, and another was excluded after histological evaluation showed no evidence of meniscus transection (OA did not develop). Remaining rats underwent gait assessments on post-surgery weeks 3, 5, 7, 8, 9, 10, and 11, and tactile sensitivity testing on post-surgery weeks 1, 2, 3, 4, 5, 7, 8, 9, 10, and 11. At 8 weeks after MCLT + MMT surgery, rats received either an injection of saline (n = 7) or IDO-Gal3 (n = 7) in the MCLT + MMT operated knee. At 12 weeks post-surgery, all rats were euthanized, then assessed for IL6, CCL2, and CTXII via magnetic capture and for joint damage using histological evaluations.

Because this is a first-of-its-kind study of IDO-Gal3, effect sizes were unknown; thus, a priori power analyses were conducted as sensitivity analyses. With the above targeted animal numbers, the sensitivity of the first experiment was 0.205 (f), assuming 9 repeated measures, power = 0.8, alpha = 0.5, correlation among representative measures = 0.5, and nonsphericity correction of 1. This indicates that if an effect explains more than 20.5% of the total variance, the effect is likely to be identified as significant. The original sensitivity of the second experiment was 0.305 (f) but lowered to 0.344 with the loss of animals. This sensitivity analysis assumed similar power, alpha, correlation among representative measures, and nonsphericity corrections, but reduced the number of post-operative repeated measures to 4 (G-Power). Statistical analyses are described for each method below, with all analyses performed in R Studio at α = 0.05. Study data and R statistical markdown records are available upon request.

**Detailed methods**

**Protein production**

Genes encoding NL-Gal3 (IDT, Coralville, IA, USA) and recombinant human Gal3 (OriGene, Rockville, MD, USA) were inserted into pET-21d(+) vectors between the Ncol and Xhol sites, then transformed into One Shot™ TOP10 Chemically Competent E. coli (ThermoFisher, Waltham, MA, USA). NL was amplified from the NL-Gal3 gene using PCR and mutated to have Ncol and Xhol flank the genes using the following primers: 5'-CGC TCG GAG CGC CAG AAT GCG TT-3' and 5'-GCT TAG CCA TGG CGG TCT TCA CAC TCG AAG-3'. PCR products were digested using Ncol and Xhol and reinserted into pET-21d(+) vectors. Genes encoding IDO were generously provided by Dr. Carlos Gonzalez’s Laboratory at the University of Florida. Amplification and insertion of the BamHI restriction site was performed using the following primers: 5'-CAG CTA CCA TGG CAC ACG CTA TGG AAA-3' and GAG AAC 5'-GGA CAC ACC TTC CTG CCT CAA AAG-3'. The NL-Gal3 gene was digested with Ncol and BamHI to remove the NL gene and insert the IDO gene. After overnight treatment on ampicillin (100 µg/mL) doped LB/agar plates (37°C), positive clones were used to inoculate 5 mL of LB broth containing ampicillin (100 µg/mL). Cultures were grown overnight on an orbital shaker (37°C, 220 rpm), with plasmids isolated using a Plasmid Miniprep Kit (Qiagen, Hilden, Germany).

Origami™ B (DE3) E. coli (Novagen, Madison, WI, USA) were transformed with pET-21d-Gal3, pET-21d-NL, pET-21d-NL-Gal3, or pET-21d-IDO-Gal3 vectors and selected on ampicillin (100 µg/mL) and kanamycin A (50 µg/mL) doped LB/agar plates overnight (37°C). Positive clones were used to inoculate 5 mL of LB broth containing ampicillin (100 µg/mL) overnight (37°C). Positive clones were used to inoculate 5 mL of LB broth containing ampicillin (100 µg/mL) and kanamycin A (50 µg/mL) and grown overnight (37°C, 220 rpm). Cultures were expanded in 1 L 2xTY broth containing ampicillin (100 µg/mL) and kanamycin A (50 µg/mL) and grown on an orbital shaker (37°C, 225 rpm) until the optical density reached 0.6–0.8 (λ = 600). Protein expression was induced via 0.5 mM isopropyl β-D-thiogalactopyranoside (ThermoFisher, Waltham, MA, USA) and grown on an orbital shaker (37°C, 225 rpm) until the optical density reached 0.6–0.8 (λ = 600). Protein expression was induced via 0.5 mM isopropyl β-D-thiogalactopyranoside (ThermoFisher, Waltham, MA, USA) and grown on an orbital shaker (37°C, 225 rpm) until the optical density reached 0.6–0.8 (λ = 600). Protein expression was induced via 0.5 mM isopropyl β-D-thiogalactopyranoside (ThermoFisher, Waltham, MA, USA) and grown on an orbital shaker (37°C, 225 rpm) until the optical density reached 0.6–0.8 (λ = 600). Protein expression was induced via 0.5 mM isopropyl β-D-thiogalactopyranoside (ThermoFisher, Waltham, MA, USA) and grown on an orbital shaker (37°C, 225 rpm) until the optical density reached 0.6–0.8 (λ = 600).

**Partain et al. Arthritis Research & Therapy (2023) 25:173**
USA) for 18 h (18 C, 225 rpm). Bacteria were pelleted via centrifugation, washed with PBS, and incubated for 20 min with B-PER™ bacterial protein extraction reagent (ThermoFisher, Waltham, MA, USA), 1 Pierce protease inhibitor tablet (ThermoFisher, Waltham, MA, USA), 300 units DNase I from bovine pancreas (MilliporeSigma, Burlington, MA, USA), and 100 µg lysozyme (MilliporeSigma, Burlington, MA, USA). Lysed bacteria were centrifuged, and supernatant was loaded into columns containing HisPur™ Cobalt Superflow Agarose (ThermoFisher, Waltham, MA, USA). Proteins were eluted using an imidazole gradient (0–250 mM), then centrifuged on Amicon Ultra Centrifugal Filters with a 10 kDa cutoff (MilliporeSigma, Burlington, MA, USA).

A second purification step was performed for IDO-Gal3 using size exclusion chromatography in an AKTA Pure Protein Purification System (GE Life Sciences, Marlborough, MA, USA). Molecular weight and purity were determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Endotoxin contaminants were removed via Detoxi-Gel Endotoxin Removing Columns (ThermoFisher, Waltham, MA, USA). Final endotoxin content was determined to be below 0.1 EU/mL using Pierce™ LAL Chromogenic Endotoxin Quantitation Kit (ThermoFisher, Waltham, MA, USA).

**Rat OA model**

OA was induced using the MCLT + MMT model originally described by Janusz et al. [23]. Briefly, rats were anesthetized using 2.5% isoflurane (Patterson Veterinary, Greeley, CO, USA). Right knees were aseptically prepared with betadine surgical scrub (Purdue Products, Stamford, CT, USA) and 70% ethanol in triplicate, ending with a fourth betadine scrub. Via a 1–2-cm skin incision and blunt muscle dissection, the medial collateral ligament was exposed and then transected. Knee abduction was then used to expose the medial meniscus, with the meniscus transected radially in its central portion. Joint capsule and muscle were closed with absorbable 5–0 vicryl braided sutures (Ethicon, Somerville, NJ, USA). Skin was closed with 4–0 ethilon nylon monofilament (Ethicon, Somerville, NJ, USA). For post-surgical pain, rats received subcutaneous buprenorphine (0.05 mg/kg, Patterson Veterinary, Greeley, CO, USA) peri-operatively then every 12 h for 48 h.

**Intra-articular injections**

Rats were anesthetized and aseptically prepared as described above. A 1 mL 27G x 3/8 syringe (Becton Dickinson, Franklin Lakes, NJ, USA) was inserted through the patellar ligament into the joint space. After injection, the needle was removed, gauze wetted with 70% ethanol was pressed against the injection site, and the knee was flexed.

**IVIS image analysis**

A region of interest (ROI) was drawn around the largest signal then copied to all other images. After subtracting background radiance, average radiance was calculated in the ROI. Average radiance for each animal was log10 normalized, plotted against time, then area under the curve (AUC) was calculated. Using AUCs, unpaired Student’s t-tests were conducted to evaluate clearance differences between NL and NL-Gal3 treated MCLT + MMT knees or NL and NL-Gal3 treated contralateral knees.

**Gait analysis**

Rodent gait was analyzed using our GAITOR system [24]. Briefly, high-speed videography (IDT M3, Pasadena, CA, 500 fps) and Kistler 3-axis load cells (±2 kN, Sindelfingen, Germany) were used to collect gait data during walking. Videos were analyzed to determine stride length, percentage stance time, temporal symmetry, and spatial symmetry; and force recordings were analyzed for peak vertical force at weeks 7–11 [25].

After IDO-Gal3 or saline treatment, gait differences were assessed with linear mixed effects models treating the animal identifier as a random factor. If indicated, comparison of least square group means was conducted using Tukey’s HSD corrections for multiple comparisons. For stride length, percentage stance time, and peak vertical force, data were first visualized relative to velocity, then statistically analyzed as both means and velocity-corrected residuals. For residualization, pre-treatment data (week 7) was used as the control line [24]. For stance time imbalance and gait symmetries, data were also compared to mathematical definitions for balanced and symmetric gait using Bonferroni-correct Student’s t-tests.

**Tactile sensitivity**

Fifty percent paw withdrawal thresholds were determined using Chaplan’s up-down method [26]. Here, von Frey filaments (0.6, 1.4, 2.0, 4.0, 6.0, 8.0, 15.0, and 26.0 g, Stoeeling Co., Wood Dale, IL, USA) were applied to the hind foot’s plantar region, starting with the 4.0 g filament. If paw withdrawal occurred, a less stiff filament was applied; if paw withdrawal did not occur, a stiffer filament was applied. Using these data, the force where paw withdrawal is equally likely to stimulus tolerance can be approximated [26]. Tactile sensitivity was evaluated using a linear mixed effects model treating week and group as fixed effects and animal ID as a random effect. When indicated, comparisons of least square means were conducted, correcting for compounding type 1 errors using Tukey’s HSD adjustment.
Magnetic capture

Magnetic capture was used to assess intra-articular levels of IL6, CCL2, and CTXII [27]. In magnetic capture, particles containing superparamagnetic iron oxide nanoparticles are used to magnetically precipitate target molecules from synovial fluid [28]. In this work, biotin-streptavidin binding was used to functionalize magnetic particles (Dynabeads MyOne™ Streptavidin C1, Cat. #65001, Life Technologies, Carlsbad, CA, USA) with antibodies for CTXII (cat. #AC-08F1, ImmunoDiagnostics Systems, Copenhagen, Denmark), IL6, and CCL2 (cat. #517703 and 505908, Biolegend, San Diego, CA, USA). Antibody-functionalized particles were injected into rat knees, incubated for 2 h, then washed from the joint using five 50 µL PBS washes. Particles in wash solutions were magnetically separated then washed again. CTXII, IL6, and CCL2 were released from particles via a 15-min treatment of 100 mM Glycine-Tris buffer (pH 3.1, containing 2% BSA and 2 mM EDTA). Following release, particles were magnetically separated, and supernatant was adjusted to pH 8.3.

In supernatants, CTXII was evaluated using the Cartilaps CTXII ELISA (cat. #AC-08F1, ImmunoDiagnostics Systems Cartilaps kit, Copenhagen, Denmark) according to manufacturer’s instructions. CCL2 was quantified using a rat CCL2 ELISA (Cat. # KRC1012 Life Technologies, Carlsbad, CA, USA) according to manufacturer’s instructions and buffer modifications described in Yarmola et al. [29]. IL6 was quantified using an ELISA developed from an antibody pair (biotin anti-rat IL6 detection antibody, cat. #517703, and purified anti-rat IL6 coating antibody, cat. #517701, Biolegend, San Diego, CA, USA). For this ELISA, coating antibodies were diluted in buffer containing 100 mM NaHCO₃ and 34 mM Na₂CO₃ (pH 9.5) and incubated on Nunc MaxiSorp™ microwells (Cat. #434797, ThermoFisher Scientific Inc., Waltham, MA, USA) for 30 min on a plate shaker then overnight (4°C). Plates were washed 5 times (PBS with 0.5% Tween-20), blocked for 1 h in PBS containing 2% BSA and 10% heat-treated bovine serum (blocking solution), then washed again. Samples and standards were pre-incubated with detection antibodies for 30 min at room temperature then overnight at 4°C, then added to the plate, incubated for 3 h, and washed. Avidin-HRP (100 µL, cat. #405103, Biolegend, San Diego, CA, USA) was diluted 500 times in blocking solution, incubated in the wells for 30 min, and then washed. Finally, tetramethylbenzidine substrate (100 µL) was added and incubated for 15 min, with the reaction stopped using diluted sulfuric acid (100 µL). Absorbance was then read at 450 and 650 nm.

To quantify particles, particles were re-suspended in 60 µL of PBS, sonicated (Model M1800H, Branson Ultrasonic Corporation, Danbury, CT, USA), and read for absorbance at 450 nm. Known particle concentrations were used as standards.

Following ELISA and particle quantification, biomarker levels were estimated as described in [28] with assay validation provided in [27, 28]. IL6, CCL2, and CTXII levels in rat knees were compared with one-way ANOVAs with post hoc Tukey’s HSD tests when indicated.

Histology

Knees were fixed in 10% neutral buffered formalin (Fisher Scientific, Pittsburgh, PA, USA) for 48 h, decalcified in Cal-Ex (Fisher Scientific, Pittsburgh, PA, USA) for 5 days, dehydrated using an ethanol ladder, and infiltrated with paraffin wax. Then, 10-µm frontal sections were acquired with at least one section taken at every 100 µm between the anterior to posterior meniscal horns. Slides were stained with toluidine blue; 3 sections per knee were assessed by 3 blinded graders using our histological grading software (GEKO) [30, 31]. Histological differences between IDO-Gal3-treated and saline-treated knees were assessed using Student’s t-tests.

Results

Galectin-3 (Gal3) increased local retention of NanoLuc™ Luciferase (NL, p < 0.0001, Fig. 1A). At 4 weeks post-injection, NL-Gal3 was present on the femur, patella/fat pad, meniscus, and tibia of both knees, while NL alone was not present (Fig. 1B).

The paw of MCLT+MMT-operated limbs became sensitized to touch after surgery, indicated by a decreasing 50% paw withdrawal threshold (p = 0.002, Fig. 2A). After treatment with either saline or IDO-Gal3, tactile sensitivity improved relative to pre-treatment levels (p = 0.0008), reaching the maximum of our testing range in 6 of 7 IDO-Gal3-treated animals. While the average tactile sensitivity for IDO-Gal3 and saline-treated animals did not vary, increases in tactile sensitivity thresholds relative to baseline values were larger in IDO-Gal3-treated animals relative to saline-treated animals at weeks 9–11 (p ≤ 0.041, Fig. 2B).

Prior to treatment, saline- and IDO-Gal3-treated rats used similar walking velocities (p ≥ 0.89, Fig. 3A). Following treatment, IDO-Gal3-treated rats achieved higher velocities than saline controls on week 10 and week 11 (p < 0.001, p = 0.033, respectively). Before treatment, saline- and IDO-Gal3-treated rats also used balanced, symmetric gaits. After treatment, the gait of saline treated rats became temporally asymmetric (asynchronous foot-strike sequence) at weeks 8–11, differing from IDO treatment animals at weeks 8–10 (p ≤ 0.035, Fig. 3B). While neither saline- nor IDO-Gal3-treated animals had imbalanced stance times, saline-treated animals tended to spend more time on
the contralateral limb (imbalance > 0), while IDO-Gal3-treated animals tended to spend more time on the affected limb (imbalance < 0). At weeks 8 and 9, stance time imbalance differed between saline- and IDO-Gal3-treated animals ($p \leq 0.025$, Fig. 3C). Spatially asymmetric gait patterns were not observed in either group (Fig. 3D).

Many gait parameters correlate to velocity (left column, Fig. 4). As such, velocity-dependent gait parameters were analyzed both as averages and velocity-corrected residuals, allowing for the evaluation of shifts due to and independent of velocity. In conjunction with velocity changes, differences between IDO-Gal3- and saline-treated rats were found for average left (contralateral) limb percent stance time ($p=0.04$, treatment main effect), right (operated) limb percent stance time ($p=0.005$, week-treatment interaction), stride length ($p=0.02$, week-treatment interaction), and right (operated) limb peak vertical force ($p=0.03$, treatment main effect). Specifically, differences between IDO-Gal3- and saline-treated rats were found for average left limb percent stance time at weeks 9, 10, and 11 ($p<0.05$), average stride length at weeks 9, 10, and 11 ($p<0.05$), and average right limb peak vertical force at weeks 9, 10, and 11 ($p<0.04$). Despite a significant interaction, differences at specific weeks were not detected for average right limb percent stance time. Peak vertical forces were similar in the left and right hind limbs of IDO-Gal3-treated rats, indicating balanced weight bearing. Saline-treated rats

**Fig. 1** Joint retention and 4-week post-injection joint distribution for knees injected with NL and NL-Gal3. A The joint residence of NL-Gal3 was significantly longer than the joint residence of unconjugated NL in both MCLT+MMT operated and contralateral joints ($p < 0.0001$, linear mixed effects model). Data are presented as mean ± 95% confidence interval. B Post-mortem analysis of luminescence at 4 weeks after injection demonstrated the presence of NL-Gal3 on the femur, patella/fat pad, meniscus, and tibia of MCLT+MMT operated and contralateral joints. Unconjugated NL was not found.
reduced loads on the operated limb relative to their contralateral limb at weeks 9 and 11 (Supplemental Fig. 3). Again, to correct for velocity effects, residuals were calculated using week 7 data as the control line. Following velocity corrections, shifts in ground reaction forces were only significant in saline-treated animals at week 9.

At 4 weeks after intra-articular injections, interleukin-6 (IL6) levels in saline-treated knees were elevated relative to contralateral controls ($p=0.0025$); moreover, IDO-Gal3-treated knees had lower IL6 levels relative to...
Fig. 3 (See legend on previous page.)
saline-treated knees ($p=0.0021$, Fig. 5A). A similar trend occurred for intra-articular levels of CCL2 and CTXII, but neither CCL2 nor CTXII were statistically elevated in saline-treated knees compared to contralateral controls ($p=0.073$, $p=0.090$, respectively). As such, shifts due to IDO-Gal3 treatment were also not statistically significant (Fig. 5B, C).

Please note, at the time of injection (8 weeks after MMT surgery), full thickness cartilage lesions are expected [24]. As such, all MCLT + MMT operated knees had marked cartilage damage. Treatment with IDO-Gal3 did not markedly alter cartilage histological measures, osteophyte size, or medial capsule thickness. However, IDO-Gal3-treated knees had lower epiphyseal trabecular bone area relative to saline controls ($p=0.031$, Fig. 6). At end point, no evidence of cartilage or meniscal damage was seen in the lateral compartment of either group.

**Discussion**

The goal of this experiment was to explore IDO-Gal3's ability to alter OA-associated inflammation and pain-related behaviors in a rat model of established knee OA, delivering IDO-Gal3 only after the onset of OA-related symptoms. These data demonstrate the ability to modulate pain-related behaviors, including animal gait and tactile allodynia, which corresponded to decreased intra-articular levels of IL6. Moreover, these effects were sustained out to 4 weeks after a single intra-articular dose of IDO-Gal3. Combined, these data demonstrate a strong potential to provide long-term control of OA-associated inflammation and symptoms using enzyme-based therapies, though additional investigations are needed and this proof-of-principle study does have limitations. This discussion both highlights the unique findings of this study relative to the field, as well as the caveats and limitations of our results and study design.

First, many preclinical OA studies deliver therapeutics prior to or shortly after joint injury [32–35], when joint remodeling and pain-related behaviors are minimal. However, pain is the primary reason OA patients seek treatment [36]. To this end, our experimental design is somewhat unique, evaluating the therapeutic potential of IDO-Gal3 only after behaviors indicative of OA pain had developed. Histologically, MCLT + MMT surgery causes significant cartilage damage by 8 weeks post-surgery. Due to cartilage’s limited repair capacity, treatment at 8 weeks post-surgery was not necessarily anticipated to improve cartilage parameters. However, IDO-Gal3 treatment did alter IL6 levels, reduce tactile sensitivity, and improve gait parameters. Moreover, subchondral bone grades followed these changes in inflammation and behavior, where epiphyseal trabecular bone area indicated less area dedicated to trabecular bone and more area to marrow voids, trending toward percentages seen in healthy knees (approximately 60%, [31]). As such, it is plausible that treatment with IDO-Gal3 shortly after joint trauma could arrest OA progression, and further studies should be conducted to address this question.

Inflammation is widely recognized as a key mediator of both joint destruction and OA pain [37, 38]. Related to inflammation, several metabolic pathways are altered in OA joints, including tryptophan metabolism [39]. Within the tryptophan pathway, IDO modulates the immune system primarily through local depletion of L-tryptophan and production of kynurenines [40]. Recent work suggests IDO-driven shifts in local metabolites can cause immunomodulatory effects on T cells and antigen presenting cells [41]. Consistent with these findings, the transfection of IDO plasmids into PMA-differentiated THP-1 (dTHP-1) cells results in increased expression of anti-inflammatory markers and decreased expression of pro-inflammatory markers [17]. Due to inflammation, IDO is often upregulated in antigen presenting cells...
and these antigen presenting cells can then activate regulatory T cells, inhibit effector T cell responses, and attenuate pro-inflammatory responses [42]. Taken together, this literature support IDO’s ability to restrain pro-inflammatory cascades; however, the specific immunomodulatory effects of IDO in OA are unanswered by the present study. This work only examines a single endpoint measure of one cytokine, one chemokine, and one
Fig. 5  Intra-articular levels of IL6, CCL2, and CTXII at 4 weeks after intra-articular injection of IDO-Gal3 or saline in MCLT + MMT operated knees (Week 12 timepoint). At 4 weeks after intra-articular injection (Week 12 timepoint), joint levels of IL6 were significantly decreased in the IDO-Gal3-treated operated knees compared to saline-treated operated knees (A, \( p = 0.03 \)). Intra-articular levels of CCL2 (B) and CTXII (C) were not elevated in saline-treated operated knees compared to contralateral controls, and as such, shifts due to IDO-Gal3 treatment could not be detected (\( p = 0.073 \) for CCL2 and \( p = 0.090 \) for CTXII). Bars represent mean ± 95% confidence interval.

Fig. 6  Histological scores of joint remodeling. At 12 weeks after surgery and 4 weeks after intra-articular injection, similar degrees of cartilage damage are seen in IDO-Gal3- and saline-treated knees (A). In scoring the histological images, tibial plateau width (B), total affected cartilage width (C), medial joint capsule width (D), synovial cell density (E), and osteophyte area (F) were similar for IDO-Gal3- and saline-treated groups. Epiphyseal trabecular bone area was lower in IDO-treated animals relative to saline controls, indicating marrow voids in the trabecular region were larger in IDO-Gal3-treated animals (G, \( p = 0.031 \)). Bars represent mean ± 95% confidence intervals.
marker of cartilage degeneration; and while these data are promising, additional work is needed to evaluate local immune cell function and phenotype in response to IDO-Gal3 delivery. Nonetheless, this proof-of-principle work strongly motivates these future studies.

IDO has been explored in other forms of arthritis, primarily rheumatoid arthritis. Here, studies have focused on assessment of downstream metabolites and intra-articular inflammatory loads, rather than behavioral assays. For example, IDO inhibition in collagen-induced arthritis (CIA) increased disease severity and elevated Th1 and Th17 responses in the joint [14, 43]. Related to this, intra-articular injection of dendritic cells modified to overexpress IDO reduced joint damage in the CIA model [44]. However, inability to sustain IDO’s effects has limited progress [45]. Our approach using an IDO-Gal3 fusion protein may overcome these issues, and IDO-Gal3 delivery in other forms of arthritis should be explored in addition to this study, which focuses on OA. Moreover, since OA tends to be associated with low inflammatory loads relative to other arthritides, these studies could provide other opportunities to evaluate IDO-Gal3’s inflammatory effects.

The goal of our first experiment was to demonstrate sustained intra-articular residence time of an enzyme due to Gal3 conjugation. Here, joint residence of nanoluciferase (a reporter enzyme) was extended by Gal3 conjugation relative to no conjugation. Supplemental Table 1 provides a comparison of the material characteristics of nanoluciferase, nanoluciferase-Gal3, IDO, and IDO-Gal3. While changes in size, charge, and hydrophobicity are expected to change the retention times for a molecule within the joint [2], these data provide sufficient evidence that the galectin-3 modification provides for an extension of joint retention beyond that expected by the material properties alone. Here, Gal3 has an affinity for β-galactosides found on extracellular matrix proteins, cell surface receptors, and lubricin [46–48]; Gal3 also binds sulfated glycosaminoglycans, like chondroitin sulfate, which is abundantly found in healthy cartilage [21]. However, in our data, operated and contralateral joints had similar nanoluciferase retention, suggesting Gal3 is not primarily binding to chondroitin sulfate in cartilage (which is lost as OA develops). Nonetheless, Gal3 conjugation extended joint residence in healthy and OA-affected joints, showing luminescence signal across multiple tissues at 4 weeks after injection in both healthy and OA-affected joints.

A limitation of our bioluminescence tracking approach was the need for repeated injections of furimazine, the substrate for nanoluciferase. It is not known how repeated injection of furimazine will affect joint clearance rates of a Gal3 fusion protein, though it is expected that the additional fluid in the joint would likely accelerate joint clearance through arthrocentesis-like effects. At the time of these experiments, a fluorescently-labeled IDO-Gal3 was not available, and follow-up experiments should further verify our results using alternative methods. Nonetheless, these results reflect the complexity of enzyme-based therapeutic approaches, which are both dependent on the amount of drug delivered and the available substrate.

Use of Gal3 to extend joint residence requires careful consideration. Unconjugated Gal3 can have pro-inflammatory actions; however, these actions require that Gal3 can cluster cell surface receptors via an oligomerization that initiates cell adhesion, differentiation, or apoptotic signals [49]. As shown in our prior work, conjugation of Gal3 to another protein prevents this action and limits these pro-inflammatory effects [22]. Moreover, screens of synoviocyte viability in preparation for this study confirmed that IDO-Gal3 was not cytotoxic for the doses used in this study (Supplemental Fig. 4).

The goal of our second experiment was to evaluate IDO’s ability to modulate OA-associated inflammation and symptoms. For inflammation, IDO-Gal3 was injected into knees with established OA, where chronic low-grade inflammation is expected. At 4 weeks post-injection, IDO-Gal3 significantly decreased intra-articular IL6 levels. IDO-Gal3 tended to have similar effects on CCL2 and CTXII; however, in saline-treated animals, neither CCL2 nor CTXII were significantly elevated in MCLT+MMT operated knees relative to contralateral controls. Thus, any effects related to IDO-Gal3 delivery were not detectable in our statistical analyses. While we have previously detected elevated CCL2 and CTXII levels in rodent OA models [27, 29], this was in untreated animals and saline injection may have reduced effect sizes to some degree. To some degree, this was seen in the tactile sensitivity results, where saline also caused some therapeutic effects. Nonetheless, IDO-Gal3 did affect IL6 levels at 4 weeks after injection, demonstrating potential to provide sustained effects on OA-associated inflammation.

For symptoms, IDO-Gal3 delivery improved gait characteristics and tactile sensitivity, whereas saline delivery only altered tactile sensitivity (and at a lower effect size relative to IDO-Gal3). Importantly, these behaviors are not necessarily expected to align. Tactile sensitivity is coupled to reflexes regulated from the spinal cord level down [50], whereas gait changes may be related to both mechanical changes in the joint, adaptive changes in the extra-articular muscle, and selected changes related to the avoidance of movement-evoked pain. Behavioral data alone do not yield sufficient resolution to evaluate which neural networks are regulated by
IDO-Gal3 delivery, but again, these data strongly motivate future experiments exploring these networks.

In rodent OA models, gait compensations can be unilateral (limping) or bilateral (shuffle-stepping), even for unilateral injury [24]. Because both unilateral and bilateral compensations reduce loading on the injured limb [25], peak vertical force often provides the most sensitive gait variable for the evaluation of OA effects in rodents. Here, IDO-Gal3-treated rats had increased loading on the operated limb relative to saline-treated animals at weeks 9, 10, and 11. Shifts in dynamic limb weight bearing were confirmed by spatial and temporal shifts in the gait cycle. For example, IDO-Gal3-treated rats also used symmetric and balanced gaits; saline-treated animals were asymmetric and imbalanced at weeks 8 and 9 and asymmetric at week 10. IDO-Gal3-treated rats also used higher walking velocities than saline-treated animals at weeks 9, 10, and 11. Finally, IDO-Gal3-treated animals used longer stride lengths than saline-treated animals at weeks 9, 10, and 11. Combined, these data demonstrate improvement in limb use (as detected via gait parameters) in IDO-Gal3-treated animals relative to saline controls.

Gait parameters that are correlated to walking velocity were first shown as raw values, then analyzed as both average values and differences that were residualized to pre-treatment data. After accounting for velocity differences, the gait profiles of IDO-Gal3- and saline-treated animals were no longer statistically significant. This indicates IDO-Gal3-treated animals did not use fundamentally different gait; instead, IDO-Gal3-treated animals achieved higher functional limb use (higher limb forces, longer stride lengths, improved stance times) via the use of faster walking velocities. Combined with the use of symmetric and balanced gaits, these data demonstrate a strong improvement in joint use for rats injected with IDO-Gal3.

Again, testing of tactile sensitivity evaluates withdrawal reflexes related to limb hypersensitivity [50]. Here, IDO-Gal3 treatment substantially increased paw withdrawal thresholds relative to pre-treatment levels, with all but one IDO-Gal3-treated rat markedly increasing their paw withdrawal threshold after injection. Withdrawal thresholds also tended to increase with saline treatment, but to a lesser extent. The therapeutic effects of a saline injection are likely related to an arthrocentesis-like “wash-out” of the joint, though these effects lasted longer than expected. Inclusion of a no treatment control would have provided additional information on the therapeutic benefit of IDO-Gal3 relative to no treatment, and this control should be considered for subsequent experiments evaluating IDO-Gal3.

The limitations of the study include the loss of magnetic nanoparticles in a subset of our animals, lowering statistical power of our intra-articular inflammation analysis. Additionally, because intra-articular inflammation was prioritized in this study, the direct assessment of metabolites in synovial fluid was not possible. Furthermore, therapeutic efficacy was not evaluated as a function of dose or time after administration. We intend to evaluate these parameters in follow-up studies. Nonetheless, these data demonstrate proof-of-principle that intra-articular delivery of IDO-Gal3 can alter OA-related behaviors in animals with established knee OA with a corresponding shift in intra-articular IL6 levels.

**Conclusions**

In this study, a novel enzyme-based therapeutic was tested in a rat model of established knee OA. First, we demonstrated that Gal3 conjugation can extend the joint residence of a reporter enzyme out to 4 weeks. Moreover, intra-articular injection of IDO-Gal3 in the OA-affected limb produced sustained effects on rodent walking, improved tactile sensitivity, and decreased IL6 levels. These data demonstrate the potential of IDO-Gal3 to serve as a metabolic reprogramming strategy for long-term, control of intra-articular inflammation, and OA-related pain. Future studies will evaluate how intra-articular delivery of IDO-Gal3 modifies joint metabolism, immune cell polarization, and progression of joint damage in additional rat OA models.

**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>OA</td>
<td>Osteoarthritis</td>
</tr>
<tr>
<td>IDO-Gal3</td>
<td>Indoleamine 2,3-dioxygenase and galectin-3 fusion protein</td>
</tr>
<tr>
<td>IDO</td>
<td>Indoleamine 2,3-dioxygenase</td>
</tr>
<tr>
<td>Gal3</td>
<td>Galectin-3</td>
</tr>
<tr>
<td>NL</td>
<td>NanoLuc™</td>
</tr>
<tr>
<td>NL-Gal3</td>
<td>NanoLuc™ and Gal3</td>
</tr>
<tr>
<td>MCLT</td>
<td>Medial collateral ligament transection</td>
</tr>
<tr>
<td>MWT</td>
<td>Medial meniscus transection</td>
</tr>
<tr>
<td>NSAID</td>
<td>Non-steroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>IL6</td>
<td>Interleukin 6</td>
</tr>
<tr>
<td>CC2</td>
<td>Chemokine ligand 2</td>
</tr>
<tr>
<td>CXTII</td>
<td>C-terminal cross-linked telopeptide of type II collagen</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate-buffered saline</td>
</tr>
<tr>
<td>B-PER</td>
<td>Bacterial protein extraction reagent</td>
</tr>
<tr>
<td>ROI</td>
<td>Region of interest</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the curve</td>
</tr>
<tr>
<td>GAITOR</td>
<td>Gait analysis instrumentation and technology optimized for rodents</td>
</tr>
<tr>
<td>HSD</td>
<td>Honestly significant difference</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosassay</td>
</tr>
<tr>
<td>GEKO</td>
<td>Graphic user interface for evaluating knee osteoarthritis</td>
</tr>
<tr>
<td>PMA</td>
<td>Phorbol myristate acetate</td>
</tr>
</tbody>
</table>
**Supplementary Information**

The online version contains supplementary material available at [https://doi.org/10.1186/s13075-023-03153-0](https://doi.org/10.1186/s13075-023-03153-0).

**Additional file 1: Supplemental Fig. 1.** Flowchart describing the experimental design used to assess the joint residence and joint distribution of an enzyme after conjugation to galectin-3. Sixteen 3-month old, male Lewis rats underwent medial collateral ligament transection plus medial meniscus transection (MCLT+MMT) surgery. At 8 weeks after MCLT+MMT surgery, rats were injected with either NanoLuc™ (NL, n=8) or NanoLuc™ galectin-3 (NL-Gal3, n=8) in both the operated and contralateral knees. Following NL or NL-Gal3 injection, rats were injected with the NL substrate, furimazine, and immediately imaged. Furimazine injections and IVIS imaging were repeated 1, 2, 4, 8, 12, 16, 20, 24, and 28 days after injection. After imaging on day 28, rats were euthanized and knees were dissected to isolate the patellar tissue, tibial tissue, femoral tissue, and meniscus for assessment of joint distribution.

**Additional file 2: Supplemental Table 1.** Estimated physical properties for NL, NL-Gal3, IDO, and IDO-Gal3.

**Additional file 3: Supplemental Fig. 2.** Flowchart describing the experimental design used to assess the ability of IDO-Gal3 to modulate OA-related pain and inflammation. Sixteen 3-month old, male Lewis rats underwent baseline gait and tactile sensitivity testing, then MCLT+MMT surgery.

**Additional file 4: Supplemental Fig. 3.** Peak vertical force measurements before and after intra-articular injection of IDO-Gal3 or saline into MCLT+MMT operated knees. This figure provides an alternate visualization of data presented in Fig. 4D and E, placing the left and right limbs of saline and IDO-Gal3 animals next to each other. Here, saline animals showed lower peak vertical forces in their affected limbs at week 9 and week 11 (p<0.003). After residualizing data to the week 7 control line, differences at week 9 remained (p=0.009), while differences at week 11 were no longer significant.

**Additional file 5: Supplemental Fig. 4.** Synoviocyte viability after exposure to Gal3, IDO, and IDO-Gal3, as visualized with a LIVE/DEAD™ Cell Imaging Kit. In a preliminary experiment, rat synoviocyte viability after exposure to IDO-Gal3 was assessed via LIVE/DEAD™ Cell Imaging Kit (R37601, Invitrogen, Carlsbad, CA, USA) following manufacturer’s instructions. Cells were grown to 70%-80% confluence. Then, synoviocytes were incubated with Triton X-100, tryptophan free media, kynurenine-supplemented media (2080 µg/mL), tryptophan free media with a kynurenine supplement (2080 µg/mL), Gal3-supplemented media (8.3 µg/mL), IDO-supplemented media (12 µg/mL, and IDO-Gal3-supplemented media (2.37 µg/mL) (n=5/group) for 24 hrs. Concentrations of tryptophan and kynurenine were selected to be 100x greater than levels found in the OA joint (12.67 mM/mL and 8.74 µg/mL, respectively). IDO concentrations were based on necessary levels to affect 100x concentrations of tryptophan in a 24 hrs period. Synoviocyte death was not observed in tryptophan free media, kynurenine-supplemented media, tryptophan free media with a kynurenine supplement, Gal3-supplemented media, IDO-supplemented media, and IDO-Gal3-supplemented media. Treatment with Triton X-100 (positive control) elicited complete cell death.

**Acknowledgements**

The authors would like to thank Natalie Thurlow and Mallory Box for assisting with gait processing. The authors would also like to acknowledge Nicole Selig for sectioning and staining samples for histology, and Kiara Chan, Jacob Griffin, and Jessica Aldrich for grading histological images. We would also like to thank Sabrina Freeman for providing scientific and technical support regarding IDO.

**Authors’ contributions**

BDP conducted and analyzed in vitro viability experiments, clearance and biodistribution experiments, tactile sensitivity experiments, gait analysis, and histological experiments. EBS expressed and purified IDO-Gal3. SAF expressed and purified NL-Gal3. EGY performed magnetic capture experiments and analyzed data with BDP. KDA performed MMT surgeries. BDP, EBS, BGK, GAH, and KDA contributed to the study design and data interpretation. The manuscript was prepared by BDP with critical feedback from all authors. All authors agree with the content and interpretation of the data as presented.

**Funding**

The work was supported by the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (Grant R01AR068424, R01AR071431, R01AR098764) and NIH/National Institute of Dental and Craniofacial Research (Grant R01DE027301).

**Availability of data and materials**

The data that support the findings of this study are available from the corresponding author, KDA, upon reasonable request.

**Declarations**

**Ethics approval and consent to participate**

All animal experiments were approved by the University of Florida Institutional Animal Care and Use Committee.

**Consent for publication**

Not applicable.

**Competing interests**

KDA is part of a patent on the magnetic capture technology (U.S. Patent No. 10,695,036). BGK and GAH are founders, hold stock, and serve on the scientific advisory board of Anchor Biosciences, Inc. The University of Florida has pending patents related to molecules and their uses reported in this paper.

**Received: 29 March 2023 Accepted: 27 August 2023**

**Published online: 18 September 2023**

**References**


Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.